ACTRN12624000784516
Not yet recruiting
未知
Evaluating the safety, tolerability and efficacy of the ketogenic diet therapy in adults with chronic migraines
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Migraine
- Sponsor
- Alfred Health
- Enrollment
- 25
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 18\-60 at time of enrolment
- •\- At least a 1\-year history of migraine, and current diagnosis of chronic migraine for three months (The International Classification of Headache Disorders 3 (ICHD\-3 criteria)
- •\- No change in migraine treatment in the preceding three months prior to enrolment
Exclusion Criteria
- •\- Body mass index less then 18\.5kg/m2
- •\- Fatty acid or amino acid oxidation disorder
- •\- Pre\-existing renal and/or liver failure
- •\- Known diagnosis of diabetes mellitus
- •\- History of pancreatitis
- •\- HbA1c greater then or equal to 6%
- •\- Prior history of eating disorder that the treating clinician or dietitian reasonably considers may be exacerbated by dietary therapy
- •\- Women who are pregnant, breastfeeding or planning to become pregnant during the study
- •\- Allergy to medical adhesives
- •\- Unable to participate in study visits.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A clinical trial to study the effect of a Under eye Skin cream containing Biophytex LS 8740 and Proteasyl TP LS 8657 in patients with under eye dark circles.CTRI/2010/091/001346Glenmark Pharmaceutical limited500
Completed
Phase 4
A clinical trial to assess the efficacy, safety and tolerability of tigecycline in adult hospitalized patients with community acquired pneumonia (CAP).Health Condition 1: null- community acquired pneumonia (CAP)CTRI/2010/091/001439Glenmark Pharmaceuticals Limited120
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
Not Applicable
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150